Please ensure Javascript is enabled for purposes of website accessibility
Alex Carchidi

Alex Carchidi

TMFacarchidi

Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.

Recent articles

GettyImages-1215331788

Is Biogen a Buy After the Latest Aduhelm Disaster?

Only if you're (really) brave.


man gets covid test

Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

It didn't work out that way in 2021.


cannabis worker compares plants

HEXO Stock: Bull vs. Bear

It might be able to outgrow its profitability issues, but the jury's still out.


worker holds coronavirus vaccine syringe

Better Buy: Novavax vs. Moderna

Both of these coronavirus vaccine innovators have plenty of upside in 2022.


Healthcare coworkers using digital tablet at hospital

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

Their products are indispensible, and their continued growth is nearly guaranteed.

vet holds dog

Buy and Hold This Unstoppable Growth Stock for the Next Decade

When it comes to raking in recurring revenue, this company is a king.


farmer inspects marijuana plant in greenhouse

Sundial Growers Stock: Bull vs. Bear

This stock isn't a slam dunk, but it could be ripe for a turnaround.


GettyImages-493302504

2 Under-the-Radar Biotech Picks to Buy For The Long Haul

These quiet biotechs are tightly focused and practically alone in their markets.


three doctors and three nurses discuss a readout at a table

Bristol Myers Squibb Stock: Bull vs. Bear

The next few years might be hard for shareholders expecting outperformance.


pharmacist stands in pharmacy

Better Buy: Viatris vs. AbbVie

Both face headwinds -- and future opportunities.

surgeon controls robotic surgical unit

Could Intuitive Surgical Stock Hit $500 in 2022?

If it makes a major new announcement, it just might be possible.


GettyImages-1201024604

3 Things About Novavax That Smart Investors Know

2022 will be a watershed year for the company in more ways than one.


doctor loads syringe with vaccine

What Are the Best Vaccine Stocks to Own in 2022?

The most-advanced vaccine developers will continue to lead the pack.


GettyImages-1251612669

This Wildly Undervalued Cannabis Stock Could Go Parabolic in 2022

This profitable growth stock is primed for success, and it's trading cheaply, too.


scientist works at lab bench

2 Top Healthcare Stocks Ready for a Bull Run in 2022

They've strongly outperformed the market in the past, and they could easily do it again.

teenager walks with backpack and bandaid on arm

Where Will Novavax Be in 3 Years?

Its revenue could be even higher than it is today.


customer examines marijuana edibles in dispensary

Could Cannabis Legalization Harm Innovative Industrial Properties Stock?

Yes, but it could be a massive boon just as easily.


doctor vaccinates teenager

What Does the Omicron Variant Mean for Vaccine Stocks?

It looks like the winners will keep winning.


doctor loads syringe in front of patient

What in the World Is Going on With Novavax Stock?

It's being simultaneously battered by setbacks and buoyed by optimism.


a senior man looks out the window

Is It Too Late to Buy Longeveron Stock?

No, but make sure you understand what you're getting into.